Study identifier:D4191R00053
ClinicalTrials.gov identifier:NCT06008353
EudraCT identifier:N/A
CTIS identifier:N/A
A Real-World Assessment of the demographic, clinical characteristics and outcomes of a Brazilian cohort of Previously Untreated Extensive Stage-Small Cell Lung Cancer receiving Durvalumab combined with Platinum-Etoposide in (ES-SCLC) in Brazil
Extensive-stage Small-cell Lung Cancer
N/A
No
-
All
60
Observational
18 Years - n/a
Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Aug 2024 by AstraZeneca
AstraZeneca
AstraZeneca
No locations available
Arms | Assigned Interventions |
---|---|
Adult patients newly diagnosed with ES-SCLC The study will include consecutive adult patients newly diagnosed with ES-SCLC (patients with the recurrent limited stage disease are also eligible). | - |